Bio Pharma Dive
APRIL 1, 2024
The FDA could soon expand use of two multiple myeloma cell therapies as well as a top-selling medicine from Sanofi and Regeneron, while Pfizer’s years of gene therapy work might finally pay dividends.
Pharmaceutical Technology
APRIL 1, 2024
FDA has granted fast track designation to LISCure Biosciences’ investigational drug LB-P8, for the treatment of PSC.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
APRIL 1, 2024
The development of cancer vaccines has provided some hope in the battle against cancer worldwide; however, there are still many challenges to overcome when developing these life-saving treatments.
Pharmaceutical Technology
APRIL 1, 2024
Discover the groundbreaking patent by Merck & Co Inc for Tricyclic Heterocycle Compounds to combat HIV infection. Learn about the innovative formula and treatment methods for a potent solution in antiretroviral therapy.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
APRIL 1, 2024
The clearance of Voydeya as an add-on therapy for an uncommon blood disease validates a bet Alexion made on original developer Achillion five years ago.
Pharmaceutical Technology
APRIL 1, 2024
Eisai is pursuing FDA authorisations for both its monthly IV maintenance and weekly subcutaneous regimens of Leqembi.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
APRIL 1, 2024
Discover Redx Pharma's groundbreaking patent for novel compounds targeting ROCK1 and ROCK2 inhibitors. Learn about the formula, structural features, and pharmaceutical applications covered in this exclusive patent.
Fierce Pharma
APRIL 1, 2024
While the market for COVID-19 vaccines has been shrinking lately, an investigation into text messages between Pfizer CEO Albert Bourla and the European Commission’s President Ursula von der Leyen r | The European Public Prosecutor’s Office (EPPO) took over the investigation into COVID vaccine negotiations between the European Commission's president and Pfizer's CEO Albert Bourla, Politico reports.
Pharmaceutical Technology
APRIL 1, 2024
Discover the innovative patent by Jubilant Pharmova Ltd for a stable radiopharmaceutical composition of tetrofosmin, ensuring high purity and effectiveness in diagnostic imaging.
Fierce Pharma
APRIL 1, 2024
Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again. | Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again. The two most influential proxy advisory firms are rallying investors to vote against the 2024 pay proposal for Soriot at the company’s annual general meeting this month.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
APRIL 1, 2024
Treat systemic lupus erythematosus effectively with UCB SA's patented method using a specific antibody to CD154. Significant improvements in SLE indices and outcomes. Explore the potential of this innovative treatment now!
pharmaphorum
APRIL 1, 2024
Otsuka and Click Therapeutics’ Rejoyn has become the first prescription digital therapeutic (DTx) to be approved by the FDA for people with major depressive disorder
Pharmaceutical Technology
APRIL 1, 2024
Discover the groundbreaking patent by Gilead Sciences Inc for compounds to treat HIV infection, including specific chemical formulas and pharmaceutical compositions. Learn more about this innovative approach to combating the virus.
pharmaphorum
APRIL 1, 2024
Eisai has filed to extend the label for its Alzheimer’s drug Leqembi to include a once-monthly maintenance regimen
Pharmaceutical Technology
APRIL 1, 2024
Discover how Forma Therapeutics Inc's patent for USP30 Inhibitor Compounds paves the way for innovative pharmaceutical treatments, targeting specific structural configurations for effective patient care.
Fierce Pharma
APRIL 1, 2024
Shortly after Gilead Sciences teamed up with Carlyle’s Abingworth to fuel further research on its antibody-drug conjugate Trodelvy, Teva is following a similar pathway with an asthma resc | Shortly after Gilead Sciences teamed up with Carlyle’s Abingworth to fuel further research on its antibody-drug conjugate Trodelvy, Teva is following a similar pathway for an asthma rescue inhaler.
Pharmaceutical Technology
APRIL 1, 2024
Discover Lonza Group Ltd's patented capsule composition with pullulan, a unique setting system, and surfactant system. This innovative capsule includes specific mineral content and is made using an organic fermentation process. Explore the details in US Patent Publication Number: US11878079B2.
Intouch Solutions
APRIL 1, 2024
March is a month of empowerment, reflection, and celebration as we recognize Women’s History Month. It’s a time to honor the remarkable achievements, resilience, and contributions of women throughout history. During the month we hosted a variety of activities led by women including the popular “Coffee Break Speaker Series: Women’s History Month” edition featuring discussions facilitated by Joanna Derma, SVP, Head of Client Service and PMO, EVERSANA INTOUCH ® , and Kate Joy, Senior Partner, EVERS
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
APRIL 1, 2024
Revolutionize your gas chromatography analysis with Yuhan Corp's patented heater integrated GC column device. Achieve precise temperature control and rapid changes for efficient compound separation and analysis.
pharmaphorum
APRIL 1, 2024
AstraZeneca’s Voydeya has been approved by the FDA as an add-on to treatment with Soliris or Ultomiris for rare disease PNH
Pharmaceutical Technology
APRIL 1, 2024
Discover the innovative method patented by A. Menarini for generating massively parallel sequencing libraries, ensuring efficient and accurate DNA sequencing. Explore the detailed process now!
Pharmaceutical Commerce
APRIL 1, 2024
Patients should not have to wait to access the medication they need.
Pharmaceutical Technology
APRIL 1, 2024
Reduce cocaine use and prevent relapse with Novartis AG's mavoglurant patent. Administering 200mg twice daily shows promising results in treating symptoms of depression and anxiety in patients with cocaine use disorder.
Pharmaceutical Commerce
APRIL 1, 2024
The latest news for pharma industry insiders.
Drug Channels
APRIL 1, 2024
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Click here to see the original post from December 2023. Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year.
Pharmaceutical Commerce
APRIL 1, 2024
Cross-sectional study explores the impact of this monumental Supreme Court ruling.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
APRIL 1, 2024
What analysts viewed as a potential “inflection point” for Eisai and Biogen’s slow-footed Leqembi is facing a delay with the FDA. | What analysts viewed as a potential “inflection point” for Eisai and Biogen’s slow-footed Leqembi is facing a delay with the FDA.
Drug Patent Watch
APRIL 1, 2024
This chart shows the pharmaceutical companies with the most ointment dosed drugs. For a different perspective, see the most popular dosage types.
Fierce Pharma
APRIL 1, 2024
With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on the market for the condition, Novartis’ Fabha | With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on the market for the condition, Novartis’ Fabhalta, AstraZeneca has answered in the United States for its add-on oral treatment in the indication.
Drug Patent Watch
APRIL 1, 2024
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
307 
Let's personalize your content